Sygnature Chemical Services and Heptares Therapeutics Announce Contract Chemistry Collaboration
News Oct 09, 2009
Sygnature Chemical Services Ltd. and Heptares Therapeutics Ltd. announced that they have entered into a contract chemistry collaboration in drug discovery.
Under the terms of the agreement, scientists from the two companies are working together to advance one of Heptares’ internal high-value GPCR programmes. Sygnature is providing synthetic chemistry services to produce a novel chemical library for Heptares to evaluate against purified, stabilized and functional proprietary GPCR targets (known as StaRs™, Stabilized Receptors).
Commenting on the agreement, Dr Simon Hirst, Sygnature’s Chief Executive Officer, said, “We are delighted that Heptares has chosen to collaborate with Sygnature on this programme. Heptares’ decision to work with us demonstrates our growing reputation for delivering ‘top tier’ science coupled with high value and quality. Over the past five years, Sygnature has established an excellent track record of success and enjoyed healthy growth because of its ability to deliver flexible scientific resource and drug discovery expertise, without high overhead costs. We look forward to building a long-term scientific and business relationship with Heptares.”
Dr Miles Congreve, Head of Chemistry at Heptares said, "We are working with Sygnature on this drug discovery programme which forms a component of our efforts to develop novel GPCR-focused therapeutics. Sygnature is becoming well-known and respected within the pharmaceutical industry for its high-quality medicinal and synthetic chemistry driven services. Sygnature was therefore our choice as a trusted partner to leverage our own internal drug discovery capabilities.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.